InvestSMART

Epiminder Limited (ASX:EPI)

ALERT: Price-sensitive ASX Announcement for EPI
Current share price for EPI : $0.265 -0.08 (-23.19%)+
Announcement
Release
16 Jul 2026 9:08AM
Price at Release
$0.345
Full Release
download
Summary
Epiminder Limited announced the enrolment of the 50th patient in its DETECT clinical study ahead of schedule, reflecting strong recruitment momentum across 20 leading US epilepsy centers. The DETECT study is evaluating the FDA-approved Minder® System, which offers continuous EEG monitoring to address diagnostic gaps in drug-resistant epilepsy. The company remains on track to meet the target of enrolling 210 patients by the end of the first half of 2027. An investor webinar is scheduled for July 30, 2026, to update on progress since the company's IPO.
Key Points
  • 50th DETECT enrolment achieved ahead of target
  • Epiminder is a pioneer in medical device technology for epilepsy
  • Minder® System is an FDA-approved continuous EEG monitoring device
  • 20 US epilepsy centers actively participating in the DETECT study
  • Target to enrol 210 patients by 1H CY2027
  • Investor webinar scheduled for July 30, 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.